Finding: Although aleglitazar reduced glycated hemoglobin and improved serum hdl-c and triglyceride levels, the drug did not decrease the time to cardiovascular death, nonfatal heart attack, or nonfatal stroke (primary end points).
Certainty (1-5): 6